Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2024-11-05 00:00:00 ET · period of report 2024-11-04 · accession 0001787306-24-000145 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-05 | 2024-11-04 | ARQT | Matsuda Masaru | See Remarks | S - Sale | $8.68 | -5,015 | 178.3K | -3% | -$43.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-04 | S | D | 5,015 | $8.68 | 178,273 | D | — | — | (F1) The sale was made pursuant to the Issuer's mandatory sell-to-cover requirements implemented to satisfy the tax withholding obligations associated with the vesting of the Reporting Person's Restricted Stock Units ("RSUs"). (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $8.32 to $8.86, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |